All In Biotech

Drug Trial Radar · NCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers

Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

410

Actual

Start

Feb 25, 2020

Primary completion

Oct 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Immunocore LtdIndustry
Sponsor type
Industry
First posted
Feb 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.

Conditions

  • Select Advanced Solid Tumors

Interventions

  • BrenetafuspDrug

    Brenetafusp IV infusions

  • Brenetafusp and pembrolizumabDrug

    Brenetafusp and pembrolizumab IV infusions

  • Brenetafusp and chemotherapyDrug

    Brenetafusp and chemotherapy IV infusions

  • Brenetafusp and monoclonal antibodies and chemotherapyDrug

    Brenetafusp and a monoclonal antibody therapy and chemotherapy

  • Brenetafusp and tebentafuspDrug

    Brenetafusp and tebentafusp IV infusions

  • Brenetafusp and bevacizumabDrug

    Brenetafusp and bevacizumab IV infusions

  • Brenetafusp and kinase inhibitorsDrug

    Brenetafusp and oral kinase inhibitors

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Incidence of dose-limiting toxicity (DLT)sTime frame: Up to ~28 days after each dose
  2. Phase 1: Incidence of adverse events (AE) and serious adverse events (SAE)Time frame: Up to 30 days after the last dose of study therapy
  3. Phase 1: Number of participants with dose interruptions, dose reductions, or dose discontinuationsTime frame: Up to ~12 months
  4. Phase 1: Number of participants with abnormal laboratory test results (hematology)Time frame: Up to 30 days after the last dose of study therapy
  5. Phase 1: Number of participants with abnormal laboratory test results (chemistry)Time frame: Up to 30 days after the last dose of study therapy
  6. Phase 1: Number of participants with abnormal laboratory test results (coagulation)Time frame: Up to 30 days after the last dose of study therapy
  7. Phase 1: Number of participants with abnormal urinalysisTime frame: Up to 30 days after the last dose of study therapy
  8. Phase 1: Number of participants with abnormal vital signsTime frame: Up to 30 days after the last dose of study therapy
  9. Phase 1: Mean change from baseline in QTcF intervalTime frame: Up to 30 days after the last dose of study therapy
  10. Phase 2: Best overall response (BOR)Time frame: Up to ~2 years

Locations

76 sites in 17 countries. Site status is shown where the registry gives one.

  • University of California - San Diego

    La Jolla, California

  • Angeles Clinic and Research Institute

    Los Angeles, California

  • University of California Davis Comprehensive Center

    Sacramento, California

  • University of Colorado

    Aurora, Colorado

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Houston Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida

  • The University of Chicago Medical Center

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • Massachusetts General Hospital

    Boston, Massachusetts

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering

    New York, New York

  • University of Oklahoma Peggy and Charles Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Prisma Health

    Greenville, South Carolina

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Utah - Huntsman Cancer Institute

    Salt Lake City, Utah

  • University of Washington - Fred Hutchinson Cancer Center

    Seattle, Washington

  • University of Wisconsin

    Madison, Wisconsin

  • Scientia Clinical Research

    Randwick, New South Wales, Australia

  • Melanoma Institute Australia (MIA) - The Poche Centre

    Wollstonecraft, New South Wales, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • LKH - Universitätsklinikum der PMU Salzburg

    Salzburg, Austria

  • Institut Jules Bordet

    Brussels, Belgium

  • UZA

    Edegem, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Universitair Ziekenhuis Brussel

    Jette, Brussels Capital, Belgium

  • CHU de Liege

    Liège, Luik, Belgium

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Brazil

  • D'Or Institute for Research and Education

    Rio de Janeiro, Brazil

  • National Cancer Institute

    Rio de Janeiro, Brazil

  • Hospital Israelita Albert Einstein

    São Paulo, Brazil

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • CHUM Centre de Recherche

    Montreal, Quebec, Canada

  • Hopital Saint-Louis - Centre d'Onco-Dermatologie

    Paris, France

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.